| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 78661 |
DSG-PEG 5000,cas:308805-39-2,1,2-二硬脂酰-rac-甘油-3-甲氧基聚乙二醇5000 |
189 |
axc |
2025-01-02 |
| 78662 |
DOctPA(Na),cas:321883-54-9,1,2- 双辛酰-sn-甘油-3-磷酸单钠盐 |
232 |
axc |
2025-01-02 |
| 78663 |
顺反DOTMA-Cl,cas:104872-42-6,(顺反)-1,2-二油烷氧基-3-(三甲铵基)丙烷氯盐 |
212 |
axc |
2025-01-02 |
| 78664 |
(S)-DPPE,cas:71357-99-8,(S)-二棕榈酰磷脂酰乙醇胺(手性异构体) |
150 |
axc |
2025-01-02 |
| 78665 |
SLinPS,cas:322647-11-0,1-硬脂酰-2-亚油酰磷脂酰丝氨酸(钠盐) |
151 |
axc |
2025-01-02 |
| 78666 |
cas:1353897-91-2,1-棕榈酰基-2-炔丙基乙酰磷脂酰胆碱,1-palmitoyl-2-(propargylacetyl)-sn-glycero-3-phosphocholine |
168 |
axc |
2025-01-02 |
| 78667 |
DPhPC,cas:207131-40-6,二植酰磷脂酰胆碱 |
161 |
axc |
2025-01-02 |
| 78668 |
DSPE-MPEG2000,cas:147867-65-0,二硬脂酰磷脂酰乙醇胺-聚乙二醇2000 |
371 |
axc |
2025-01-02 |
| 78669 |
DPPE,cas:923-61-5,磷脂酰乙醇胺,1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine |
369 |
axc |
2025-01-02 |
| 78670 |
P-LysoPC,cas:17364-16-8,1-十六酰-sn-丙三醇-磷酸胆碱 |
220 |
axc |
2025-01-02 |
| 78671 |
DLPC,cas:18194-25-7,1,2-二月桂酰基-sn-glycero-3-胆碱磷酸 |
188 |
axc |
2025-01-02 |
| 78672 |
HSPC/Chol/DSPE-mPEG2000/MPL (56.2/38.5/4.3/1, mol/mol) Liposomes,HSPC/Chol/DSPE-mPEG2000/MPL脂质体 |
190 |
axc |
2024-12-31 |
| 78673 |
DOTAP/DOPE (50/50, mol/mol) Liposomes,DOTAP/DOPE (50/50,摩尔/摩尔)脂质体 |
229 |
axc |
2024-12-31 |
| 78674 |
Adavosertib Liposomes, Formulation WD4,阿达沃塞替布脂质体,制剂WD4 |
413 |
axc |
2024-12-31 |
| 78675 |
Mirdametinib (PD0325901) Liposomes, Formulation U6-2,Mirdametinib (PD0325901)脂质体,配方U6-2 |
284 |
axc |
2024-12-31 |
| 78676 |
DT-061 (SMAP) Liposomes, Formulation TT-40,DT-061 (SMAP)脂质体,制剂TT-40 |
206 |
axc |
2024-12-31 |
| 78677 |
Tanespimycin (17-AAG) Liposomes, Formulation XT28.1,坦那霉素(17-AAG)脂质体,配方XT28.1 |
175 |
axc |
2024-12-31 |
| 78678 |
Nexturastat A Liposomes,Nexturastat A脂质体,靶向脂质体定制服务 |
166 |
axc |
2024-12-31 |
| 78679 |
A939572 Liposomes,A939572脂质体,靶向脂质体定制服务 |
217 |
axc |
2024-12-31 |
| 78680 |
Eganelisib (IPI-549) Liposomes, Formulation WNX5.2,Eganelisib (IPI-549)脂质体,制剂WNX5.2 |
346 |
axc |
2024-12-31 |
| 78681 |
Lificiguat (YC-1) Liposomes, Formulation FNT8P.2,Lificiguat (YC-1)脂质体,制剂FNT8P.2 |
227 |
axc |
2024-12-31 |
| 78682 |
SP600125 Liposomes, Formulation HZ12,SP600125脂质体,配方HZ12 |
169 |
axc |
2024-12-31 |
| 78683 |
Rocaglamide Liposomes, Formulation KHE9A,罗卡酰胺脂质体,配方KHE9A |
167 |
axc |
2024-12-31 |
| 78684 |
Gilteritinib (ASP2215) Liposomes,吉尔替尼(ASP2215)脂质体 |
178 |
axc |
2024-12-31 |
| 78685 |
CAS:125503-35-7 双(2,5-二氧吡咯烷-1-基)2,2'-(丙烷-2,2-二基双(磺胺基)二乙酸酯) |
209 |
zhn |
2024-12-31 |
| 78686 |
AZD1208 Liposomes, Formulation RB4T4,AZD1208脂质体,配方RB4T4 |
143 |
axc |
2024-12-31 |
| 78687 |
DiR Labeled Tumor-Accumulating Liposomes邃,DiR标记的肿瘤积聚脂质体 |
224 |
axc |
2024-12-31 |
| 78688 |
氧化锌量子点(ZnO QDs) 无机半导体材料 |
299 |
zhn |
2024-12-31 |
| 78689 |
聚多巴胺微球 |
295 |
zhn |
2024-12-31 |
| 78690 |
PS-R-PMMA 聚苯乙烯(PS)和聚甲基丙烯酸甲酯(PMMA)共聚物 |
577 |
zhn |
2024-12-31 |
| 78691 |
AgBiS₂量子点 银铋硫化物量子点 |
312 |
zhn |
2024-12-31 |
| 78692 |
单层石墨相氮化碳纳米片(Graphitic Carbon Nitride, g-C₃N₄) |
418 |
zhn |
2024-12-31 |
| 78693 |
HSPC/胆固醇/DSPE-mPEG2000 (56.2/38.5/5.3,摩尔/摩尔)脂质体(DiD标记),脂质体定制服务 |
204 |
axc |
2024-12-31 |
| 78694 |
HSPC/Chol/DSPE-mPEG2000 (56.2/38.5/5.3, mol/mol) Liposomes (DiD-labeled),脂质体定制服务 |
220 |
axc |
2024-12-31 |
| 78695 |
环糊精修饰螺吡类分子 |
170 |
zhn |
2024-12-31 |
| 78696 |
HSPC/胆固醇/DSPE-聚乙二醇2000/DSPE-聚乙二醇2000-马来酰亚胺(50/45/4/1,摩尔/摩尔)脂质体,脂质体定制服务 |
192 |
axc |
2024-12-31 |
| 78697 |
二氧化硅包纳米金棒 SiO₂@Au nanorods |
173 |
zhn |
2024-12-31 |
| 78698 |
HSPC/Chol/DSPE-mPEG2000/DSPE-mPEG2000-maleimide (50/45/4/1, mol/mol) Liposomes,脂质体定制服务 |
204 |
axc |
2024-12-31 |
| 78699 |
四氧化三铁二硫化钼复合材料 Fe₃O₄@MoS₂ |
348 |
zhn |
2024-12-31 |
| 78700 |
17-(Azide-PEG9-ethylcarbamoyl)heptadecanoic t-butyl ester |
190 |
h |
2024-12-31 |
| 78701 |
14-(Azide-PEG6-ethylcarbamoyl)tridecanoic-t-butyl ester |
148 |
h |
2024-12-31 |
| 78702 |
IR-700-NH2 氨基化的近红外荧光染料 |
286 |
zhn |
2024-12-31 |
| 78703 |
HSPC/Chol/DSPE-mpeg 2000/DSPE-mpeg 2000-马来酰亚胺/MPL (49/45/4/1/1,摩尔/摩尔)脂质体,脂质体定制服务 |
164 |
axc |
2024-12-31 |
| 78704 |
14-(Azide-PEG4-ethylcarbamoyl)tridecanoic-t-butyl ester |
165 |
h |
2024-12-31 |
| 78705 |
Amine-PEG5-c18-t-butyl ester |
230 |
h |
2024-12-31 |